Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21


A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.

Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A.

Clin Cancer Res. 2019 Apr 1;25(7):2096-2108. doi: 10.1158/1078-0432.CCR-18-3496. Epub 2018 Dec 20.


IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.

Puig-Saus C, Parisi G, Garcia-Diaz A, Krystofinski PE, Sandoval S, Zhang R, Champhekar AS, McCabe J, Cheung-Lau GC, Truong NA, Vega-Crespo A, Komenan MDS, Pang J, Macabali MH, Saco JD, Goodwin JL, Bolon B, Seet CS, Montel-Hagen A, Crooks GM, Hollis RP, Campo-Fernandez B, Bischof D, Cornetta K, Gschweng EH, Adelson C, Nguyen A, Yang L, Witte ON, Baltimore D, Comin-Anduix B, Kohn DB, Wang X, Cabrera P, Kaplan-Lefko PJ, Berent-Maoz B, Ribas A.

Clin Cancer Res. 2019 Feb 1;25(3):1000-1011. doi: 10.1158/1078-0432.CCR-18-0963. Epub 2018 Nov 8.


Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.

Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, Cochran AJ, Economou JS, Tumeh PC, Puig-Saus C, Ribas A.

Cancer Discov. 2018 Aug;8(8):935-943. doi: 10.1158/2159-8290.CD-17-1178. Epub 2018 Jun 13.


Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.

Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, Comin-Anduix B.

J Immunother. 2018 Jun;41(5):248-259. doi: 10.1097/CJI.0000000000000216.


Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.

Cell. 2017 Jan 26;168(3):542. doi: 10.1016/j.cell.2017.01.010. No abstract available.


Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA Jr, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A.

Cancer Discov. 2017 Feb;7(2):188-201. doi: 10.1158/2159-8290.CD-16-1223. Epub 2016 Nov 30.


Distinct Genetic Networks Orchestrate the Emergence of Specific Waves of Fetal and Adult B-1 and B-2 Development.

Montecino-Rodriguez E, Fice M, Casero D, Berent-Maoz B, Barber CL, Dorshkind K.

Immunity. 2016 Sep 20;45(3):527-539. doi: 10.1016/j.immuni.2016.07.012. Epub 2016 Aug 23.


Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A.

N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.


Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.

Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17. Erratum in: Cell. 2017 Jan 26;168(3):542.


The expansion of thymopoiesis in neonatal mice is dependent on expression of high mobility group a 2 protein (Hmga2).

Berent-Maoz B, Montecino-Rodriguez E, Fice M, Casero D, Seet CS, Crooks GM, Lowry W, Dorshkind K.

PLoS One. 2015 May 1;10(5):e0125414. doi: 10.1371/journal.pone.0125414. eCollection 2015.


Proteolytic histone modification by mast cell tryptase, a serglycin proteoglycan-dependent secretory granule protease.

Melo FR, Vita F, Berent-Maoz B, Levi-Schaffer F, Zabucchi G, Pejler G.

J Biol Chem. 2014 Mar 14;289(11):7682-90. doi: 10.1074/jbc.M113.546895. Epub 2014 Jan 29.


Causes, consequences, and reversal of immune system aging.

Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K.

J Clin Invest. 2013 Mar;123(3):958-65. doi: 10.1172/JCI64096. Epub 2013 Mar 1. Review.


Genetic regulation of thymocyte progenitor aging.

Berent-Maoz B, Montecino-Rodriguez E, Dorshkind K.

Semin Immunol. 2012 Oct;24(5):303-8. doi: 10.1016/j.smim.2012.04.006. Epub 2012 May 2. Review.


Fibroblast growth factor-7 partially reverses murine thymocyte progenitor aging by repression of Ink4a.

Berent-Maoz B, Montecino-Rodriguez E, Signer RA, Dorshkind K.

Blood. 2012 Jun 14;119(24):5715-21. doi: 10.1182/blood-2011-12-400002. Epub 2012 May 3.


Influence of FAS on murine mast cell maturation.

Berent-Maoz B, Gur C, Vita F, Soranzo MR, Zabucchi G, Levi-Schaffer F.

Ann Allergy Asthma Immunol. 2011 Mar;106(3):239-44. doi: 10.1016/j.anai.2010.12.001. Epub 2011 Jan 13.


Human mast cells express intracellular TRAIL.

Berent-Maoz B, Salemi S, Mankuta D, Simon HU, Levi-Schaffer F.

Cell Immunol. 2010;262(2):80-3. doi: 10.1016/j.cellimm.2010.02.003. Epub 2010 Feb 6.


Are we ready to downregulate mast cells?

Karra L, Berent-Maoz B, Ben-Zimra M, Levi-Schaffer F.

Curr Opin Immunol. 2009 Dec;21(6):708-14. doi: 10.1016/j.coi.2009.09.010. Review.


Human mast cell activation by Staphylococcus aureus: interleukin-8 and tumor necrosis factor alpha release and the role of Toll-like receptor 2 and CD48 molecules.

Rocha-de-Souza CM, Berent-Maoz B, Mankuta D, Moses AE, Levi-Schaffer F.

Infect Immun. 2008 Oct;76(10):4489-97. doi: 10.1128/IAI.00270-08. Epub 2008 Jul 21.


Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a.

Bachelet I, Munitz A, Berent-Maoz B, Mankuta D, Levi-Schaffer F.

J Immunol. 2008 May 1;180(9):6064-9.


TRAIL mediated signaling in human mast cells: the influence of IgE-dependent activation.

Berent-Maoz B, Salemi S, Mankuta D, Simon HU, Levi-Schaffer F.

Allergy. 2008 Mar;63(3):333-40. doi: 10.1111/j.1398-9995.2007.01598.x. Erratum in: Allergy. 2009 Apr;64(4):666.


Human mast cells undergo TRAIL-induced apoptosis.

Berent-Maoz B, Piliponsky AM, Daigle I, Simon HU, Levi-Schaffer F.

J Immunol. 2006 Feb 15;176(4):2272-8.

Supplemental Content

Loading ...
Support Center